A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study
Emergency Medicine
[키워드] Activation
acute respiratory syndrome
Ad26.COV2.S vaccine
administration
Adverse
antibodies
AstraZeneca
benefit
Bilateral
Blood
Care
caused
CDC
center
Complication
Computed tomography
Concentration
conducted
consolidations
Control
coronavirus
Coronavirus COVID-19
coronavirus disease
COVID-19
COVID-19 patient
CTA
D-dimer
D‐dimer
deep vein thrombosis (DVT)
Deep venous thrombosis
Deterioration
Disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC)
distribution
drug
DVT
Dyspnea
effective
elevated
endotracheal
FDA
finding
food
growth
ICU
immune
immune complex
increase
Inflammation
intensive care
Intervention
intravascular coagulation
intubation
Johnson & Johnson
johnson and johnson vaccine
less
lobar
Lungs
Man
manifestation
moderate
Moderna
mRNA-based vaccine
Occurrence
oxygen
pandemic
Patient
Pfizer
Platelet
Pneumonia
positive airway pressure
prevention
pro-thrombotic
Prothrombin time
Pulmonary emboli
recipient
recipients
reported
required
response
risk
saddle pulmonary embolism
SARS-CoV-2
SARS-CoV2 infection
segmental artery
similarity
specificity
Supplemental oxygen therapy
the SARS-CoV-2
the vaccine
Thromboembolism
thrombosis
thrombotic
thrombotic thrombocytopenic thrombocytopenia
Thrombus
transferred
Vaccine
venous
venous thromboembolism (VTE)
was performed
worsened
[DOI] 10.7759/cureus.16383 PMC 바로가기 [Article Type] Emergency Medicine
[DOI] 10.7759/cureus.16383 PMC 바로가기 [Article Type] Emergency Medicine